Audited Financial Results
INDOUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indo Us Bio-Tech Limited reported audited financial results for FY2026 ended March 31, 2026. Revenue from Operations grew by 6.6% to Rs. 1,104.39 Lakhs from Rs. 1,036.33 Lakhs in FY2025. However, Net Profit After Tax declined by 19.3% to Rs. 131.23 Lakhs compared to Rs. 162.67 Lakhs in the previous year. The company operates in the seed cultivation segment and holds assets of Rs. 7,308.67 Lakhs. Statutory Auditors Gautam N Associates issued an UNMODIFIED opinion on the financial statements, though they raised an Emphasis of Matter regarding unconfirmed trade receivables, trade payables, unsecured loans, and verification gaps for cash sales to retail customers and farmers. The company also disclosed pending income tax disputes totaling Rs. 209.63 Lakhs across multiple assessment years.
While PAT remained positive, the 19.3% decline in profits and negative operating cash flow of Rs. 1,250.08 Lakhs are concerning for shareholders. The auditor's emphasis on unverified account balances adds audit risk. However, the unmodified opinion provides some comfort.